|Delayed - 01/17 11:30:35 am|
Medacta Extends the Personalized Medicine Concept to Total Knee Revision Surgeries with the Unique and Innovative MyKnee R Patient-Specific Solution10/19/2021 | 01:00pm
Medacta announced the release of MyKnee(R) R, the newest addition to its MySolutions(R) Personalized Ecosystem. MyKnee R is the unique-on-the-market patient-specific set of 3D-printed blocks that can be directly positioned on the failed primary implant in situ, in order to easily proceed with its replacement. Starting from a CT scan, MySolutions engineers create a 3D reconstruction of the patient's joint where a failed primary implant has been positioned. This reconstruction is then used to accurately plan the positioning of a new prosthesis, chosen from Medacta's portfolio of total knee replacement solutions, ranging from a minimum level of constraint (GMK(R) Sphere and GMK(R) Primary) to semi- and fully constrained solutions (GMK(R) Revision and GMK(R) Hinge). MyKnee R is the game-changing technology to facilitate the introduction to total knee revision surgeries, where even highly experienced surgeons are often confronted with complex and time-consuming cases. MyKnee R is part of Medacta's MySolutions ecosystem of personalized medicine products and technologies. Originally introduced as MyKnee(R) to address an unmet need for better implant positioning in the total knee replacement market, MySolutions can now also be used in hip (MyHip(R), MyHip(R) Planner, MyHip(R) Verifier), shoulder (MyShoulder(R)) and spine (MySpine(R)) procedures. In addition to patient-matched surgical guides, MySolutions also includes advanced planning and verification tools, augmented reality-based personalized execution, patient pathway optimization and clinical data collection and analysis. MyKnee R is also supported by a tailored educational offering. With an international network of expert surgeons, the M.O.R.E. Institute is at the forefront of education on total knee revision techniques and products with personalized high-level educational pathways, supporting surgeons with focused activities as they master revision. With Medacta the surgeon is never alone.
© S&P Capital IQ 2022
All news about MEDACTA GROUP SA